Recent News

• 06.03.2026 - On-Demand Webinar: Detecting Early Synaptic Failure in Prion Disease Using Organoid Models
• 05.27.2026 - From Data Overload to Confident Interpretation: How Advanced Analytics Improve Preclinical Telemetry Review
• 05.26.2026 - VIDEO: Getting Started with Mesh MEA - How to Sterilize & Prepare Mesh MEA for Recording
• 05.26.2026 - BTX User Spotlight: Streamlining CRISPR Genome Editing in Cryptococcus neoformans with Optimized Cas9 and Electroporation
• 05.14.2026 - Unlocking the True Impact of Weight-Loss Therapies: Why Preclinical Behavior Analysis Matters
• 05.12.2026 - Harvard Bioscience Announces First Quarter 2026 Financial Results
• 05.07.2026 - Harvard Bioscience to Participate in Upcoming Investor Conferences
• 04.28.2026 - Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
• 04.17.2026 - Subscribe to Preclinical Pulse

Recent Filings

• 06.02.2026 - 8-K Current report
• 05.27.2026 - SD Specialized disclosure report
• 05.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - EX-99.1 EX-99.1
• 05.12.2026 - 8-K Current report
• 05.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2026 - 8-K Current report
• 05.12.2026 - EX-99.1 EX-99.1
• 04.21.2026 - DEF 14A Other definitive proxy statements
• 04.21.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material